Used to treat countless individuals undergoing differing medical treatments, antibiotics can be classified as something that we take for granted. The influx of antimicrobial resistance is amplifying concerns globally. The spread of Candida auris and super-resistant gonorrhoea exemplifies the horrifying reality of antimicrobial resistance. The increased antimicrobial resistance could potentially kill 10 million people over the next thirty years – a 700,000 increase on current deaths directly related to antimicrobial resistance.
As a response to the growing threat, a UN commission has recommended an immediate and well-co-ordinated action plan be implemented and exercised to ensure that we avoid a catastrophic event that would result in dire economic outcomes that the World Bank believes could be equivalent to the global financial crisis of 2008-09.
Although pharmaceutical companies have failed in the past to conjure solutions for pressing medical issues, developments relating to antibiotics have been poor. To restrict antimicrobial resistance doctors often refrain from commonly using novel antibiotics. Novel antibiotics are seen as the last resort and are only used for short periods of time. Unlike other medicines, the price of antibiotics is often set low, giving pharmaceutical companies very minimal motivation to develop their current products further; this has the negative implication of discouraging investors from approaching and potentially working alongside antibiotic firms.